of acute myocardial infarction patients after thrombolysis or primary percutaneous intervention. 5 Patients with no-reflow may develop in-hospital major adverse cardiac events (MACE) and congestive heart failure in the early periods after myocardial infarction, and they may present with progressive left ventricular dilatation during recovery from infarction. 3 The development of no-reflow is multifactorial, and the etiology is not fully understood. 6 Although age ≥65 years, reperfusion time >4 h, a high thrombus burden, Killip class ≥3, long stent use, ejection fraction ≤40 and a high syntax score (SS) have been shown as predictors, new scales may guide interventions prior to a procedure when no-reflow is likely to develop. [7] [8] In this study, we aimed to evaluate the parameters associated with no-reflow in previous studies in terms of no-reflow and MACE prediction by creating a new scoring system.
| METHODS
The study included 515 consecutive STEMI patients who underwent PCI between July 2015 and July 2016. In addition, 632 STEMI patients who had undergone PCI in another centre between July 2015 and July 2016 were included in the external validation of the scoring system.
Written or verbal informed consent was received from all patients, and the study protocol was approved by the hospital's local ethics committee in accordance with the Helsinki Declaration and Good
Clinical Practice Guidelines. The estimated score was produced using a stepwise logistic regression, with demographic and angiographic variables that have previously been defined as predictors (age ≥65 9 The thrombosis score was assessed as previously defined by the TIMI Study Group. 10 Angiography noreflow was defined as TIMI grade <3 or myocardial blush grade <2.
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Any major coronary vessels with a diameter narrowed by 50% or more were defined as significant stenosis. If a stenosis of >50% diameter contained more than two epicardial coronary arteries, it was defined as multivessel disease. Providing TIMI III flow with <20% residual stenosis in major epicardial coronary arteries was defined as complete revascularization.
The SS was calculated using an online calculator (http://www. syntaxscore.com). Two experienced interventional cardiologists who were blinded to the study calculated the SS. In the case of contradictory results, the two cardiologists decided based on consensus.
All patients underwent coronary angiography with a transfemoral approach. Before PCI, patients were given 600 mg of clopidogrel, 300 mg of acetylsalicylic acid and 70 IU/kg of intravenous heparin.
MACE is defined as stent thrombosis, target vessel revascularization, myocardial infarction, and death.
| Statistical analysis
The data analysis was conducted using SPSS (version 20. Receiver operating characteristic (ROC) curves were used to 
| RESULTS
Among the STEMI patients, 15 of 530 patients who were accepted based on compliance with primary PCI were excluded from the study since they were not eligible between July 2015 and July 2016.
Following the primary PCI procedure, no-reflow was observed in 72 (14%) of 515 patients. In the validation arm, no-reflow was detected in 110 (17.4%) of the 632 patients. Age, pain-balloon time, stent length, Killip class, thrombus grade, SS, and EF were statistically different in the group that developed no-reflow compared to the reflow group. In addition, after these parameters were categorized, a statistically significant difference was observed between the two groups. The clinical characteristics as well as the angiographic and PCI features of the findings are listed in Table 1 .
Among the significant parameters in the univariate analysis, those that were also found to be significant in the multiple regression clinical scoring system for estimating post-procedural no-reflow. The score ranged from 0 to 19 (Table 2 ).
For the derivation group, the optimal threshold score for predicting no-reflow was >10, with a 75% sensitivity and 77.7% specificity (area under the curve [AUC]: 0.809, 95% CI: 0.772-0.842, P < 0.001) (Figure 1 ).
For the validation group, AUC was 0.793 (95% CI: 0.760-0.824, P < 0.001) ( Figure 2 ). (derivation vs. validation sample, difference: 0.016, P = 0.644).
The Hosmer-Lemeshow test produced a value of χ 2 = 7.63 (P = 0.470).
In the derivation and validation groups and in the total patient population, 1-year mortality (P = 0.012, P < 0.001, P < 0.001, respectively) and 1-year MACE, which becomes meaningful with the mortality rate (P = 0.002, P < 0.001, P < 0.001, respectively), were significantly higher in the high-risk group (score >10; Table 3 ).
| DISCUSSION
In our study, seven different parameters were found to predict the development of no-reflow in STEMI patients. The new score developed from these parameters was sensitive in predicting the development of no-reflow (AUC: 0.809). When this score was tested in the validation arm, its predictive power remained high (AUC 0.793; difference = 0.016, P = 0.644). It was observed that a high-risk value of this score may help for estimating 1-year MACE and mortality rates.
No-reflow is associated with a poor prognosis in STEMI patients treated with PCI. There are a number of factors that contribute to the development of no-reflow. [12] [13] [14] [15] An important pathophysiological mechanism is thought to be distal embolisation. 16, 17 In our study, age, EF, thrombus grade, Killip class, pain-PCI time, stent length, and SS were found to be predictors of no-reflow. T. Liang and coworkers observed that the development of no-reflow was higher in advanced age patients. 18 A higher incidence of diffuse atherosclerosis, severe calcification, distal microvessel embolization, and microvascular diseases in elderly patients are thought to cause the development of no-reflow. 19 Consistent with this, we showed that advanced age was an independent risk factor in the development of no-reflow.
Previous studies have shown that the incidence of no-reflow is higher in patients with low EFs, and that low EF is an independent predictor in the development of no-reflow. In addition, in a study by Wang et al., high Killip class (≥3) was demonstrated to be associated with the development of no-reflow. 20, 21 Similar to those studies, in the present study low EF and high Killip class were observed to be independent predictors in the development of no-reflow.
Yip et al. found that the presence of a high thrombus in STEMI was
an independent predictor of post-procedural no-reflow in patients FIGURE 1 ROC curve graphics to detect the best cut-off value for the new scoring system in predicting the no-reflow phenomenon in the derivation group undergoing PCI. 22 In addition, Sabin et al. found that high thrombus load was an independent predictor of the development of no-reflow. 6 The results of our study support this finding. Several studies have
shown that the length of the target lesion is important in the development of no-reflow. 10 In our study, the length of the stent used in the culprit lesion predicted the development of no-reflow. Several studies have shown that pain-balloon time predicts the development of no-reflow. Although this time differs among various studies, 4h, the closest to our median value of 215 min, was accepted as the cut-off value and predicted the development of no-reflow.
A higher rate of atherosclerosis was observed in patients who developed no-reflow compared to those who did not. However, noreflow develops more often in patients with a high SS. 12 This is thought to be caused by the fact that diffuse coronary artery disease is related to impaired microcirculation resistance, which affects epicardial blood flow. 23, 24 Similarly, we found a significant association between a high SS and no-reflow.
No-reflow is not a rare complication of primary PCI in STEMI patients. In the past, several scoring systems were used for the prediction of no-reflow. In their study, Yesin et al. showed that SS II could predict no-reflow. 7 Wang et al. also predicted no-reflow in the model they developed. 8 Distal thromboembolism is an important mechanism for the development of no-reflow. Thrombus aspiration, intracoronary Gp 2b/ 3a inhibitors, adenosine, calcium channel blockers and sodium nitroprusside have been used in the management of no re-flow. 17 In the present study, thrombus aspiration was performed in 12 patients (6.5%), a GP2b3a inhibitor (tirofiban, absiximab) was used in 95 patients (52.1%), adenosine was used in 78 patients (42.8%), and diltiazem was used in 26 (14.2 %) patients who developed no-reflow.
Primary PCI must be performed rapidly in STEMI patients. In the above-mentioned studies, the incorporation of laboratory parameters into the scores might be helpful for implementing post-procedural measures. However, these parameters do not enable the calculation of a risk score before the procedure. 7, 8 Unlike the previous scoring systems, we believe that the use of demographic and angiographic parameters that could be evaluated faster enable a more rapid evaluation independent of laboratory parameters, and thus this score would be helpful before PCI.
Several scores, such as the CHADS score, have been shown to have an association with mortality and morbidity. 25 In this study, a high score created by considering the cut-off value was associated with 1-year MACE, which becomes meaningful with the mortality rate.
| CONCLUSION
In conclusion, in our study, it was observed that the simple risk score generated from seven independent parameters predicted the noreflow phenomenon. Considering the high mortality associated with no-reflow, we think that this newly developed scoring system may help physicians to estimate the development of no-reflow in the pre-PCI period. However, it would be appropriate to test this score in a wider range of studies with different populations.
| Study limitations
This study has some limitations. First, this was a retrospective casecontrol type study, which can be biased compared to prospective studies. For the score, predictive efficacy needs to be further tested in a prospective and large-scale study. In our study, all patients underwent transfemoral access and received clopidogrel. Ticagrelol or prasugrel was not administered in the present study, and this may have influenced the outcomes. The relevance of the proposed risk score at centers with FIGURE 2 ROC curve for the no-reflow risk model in the validation group differing practices has not been examined. Lastly, the applicability of this predictive model in routine clinical practice is limited, as the clinical management of patients with a high probability of no-reflow is not significantly different than the management of other patients.
